This is mainly because of the reported weight loss While GLP-1 medications Zepbound and This rapid increase in users of GLP-1 drugs has caused Now, a new study published in Annals of Internal Medicine , reports that among the approximately 1 million new GLP-1 medication users identified between 2011 to 2023, there was a twofold increase in GLP-1 medication users who do not have type 2 diabetes but do have a body mass index (BMI) of 30 killograms per square meter (kg/m 2 ) or greater, and in people with a BMI of 27 to 30 kg/m 2 and an obesity-related The researchers also found that the proportion of users of GLP-1 medications without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023
If you are still deciding, complete the free assessment quiz to explore your options
#Watch #GLP1 #WeightLossDrugs #PharmaNews #IndianPharma #Semaglutide #Mounjaro #Wegovy #Ozempic #PatentExpiry #HealthcareBusiness #CNBCTV18Digital Transcript To view or add a comment, sign in More Relevant Posts Ozempic patents expire March 2026, triggering 50% price drops in India, China, Brazil
CL Answer Himalayan and Sea Salts: Health Benefits, Toxic Metals, & Microplastics Himalayan salt health benefits, along with other gourmet salts like Hawaiian and Mediterranean
